大型高血压试验发表后爱尔兰的初级保健处方模式
Primary care prescribing patterns in Ireland after the publication of large hypertension trials.
作者信息
Kabir Zubair, Feely John, Bennett Kathleen
机构信息
Department of Pharmacology & Therapeutics, Trinity Centre for Health Sciences, St James's Hospital and Trinity College Dublin, Dublin 8, Ireland.
出版信息
Br J Clin Pharmacol. 2007 Sep;64(3):381-5. doi: 10.1111/j.1365-2125.2007.02896.x. Epub 2007 Jul 4.
AIMS
This study assessed prescribing patterns of antihypertensive therapies (AHT) before and after the publication of the LIFE, ALLHAT and VALUE trials between 2000 and 2005.
METHODS
The Irish HSE-PCRS prescribing database was used to identify those initiated any AHT. Any change 12 months before and after the trial publications was examined using a segmented regression analysis.
RESULTS
There was little or no effect of any of the trials on new AHT prescribing, except for ALLHAT where there was an increase in new prescriptions for ACE inhibitors, and VALUE with a slight increase in prescriptions for calcium channel blockers.
CONCLUSIONS
Our findings show that there was little or no effect of any of the three clinical trials studied on new AHT prescribing patterns in Irish general practice. Future studies should assess any underlying barriers to implementing new evidence into clinical practice.
目的
本研究评估了2000年至2005年间《LIFE》《ALLHAT》和《VALUE》试验发表前后抗高血压治疗（AHT）的处方模式。
方法
使用爱尔兰健康服务执行局初级保健研究与临床服务（HSE-PCRS）处方数据库来确定那些开始使用任何抗高血压治疗的患者。使用分段回归分析检查试验发表前后12个月的任何变化。
结果
除了《ALLHAT》试验使血管紧张素转换酶（ACE）抑制剂的新处方增加，以及《VALUE》试验使钙通道阻滞剂的处方略有增加外，其他试验对新的抗高血压治疗处方几乎没有影响。
结论
我们的研究结果表明，所研究的三项临床试验中的任何一项对爱尔兰全科医疗中新的抗高血压治疗处方模式几乎没有影响。未来的研究应评估将新证据应用于临床实践的任何潜在障碍。
Zotero 插件